Immunocore Holdings plc

Immunocore Holdings plc (ticker: IMCR) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of IMCR's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. IMCR reported $106.68M in revenue and $12.97M for the period ending 2026-03-31, with operating cash flow of -$13.78M. Cash and equivalents stood at $452.68M (down 5.1% year-over-year). Total assets of $1.07B exceed total liabilities of $678.42M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

IMCR Cash Runway

Months-of-runway analysis for IMCR, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on IMCR

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.